Response & Biology Based Risk Factor Guided Therapy Treating Patients w/Non-high Risk Neuroblastoma
Utilizing Response and Biology Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma
-
Clinical Trial Information
Trial Contact: Spinelli, Jennifer; Parker, Melanie; Armatti, Julie M; Doyle, Katherine M; Dubberly, Paige D
Trial Phone: 321.841.5357 ; 321-843-1036 ; 321-843-5284 ; 3218412008 ; 321-841-7561
-
IRB No: ANBL1232
Protocol Abbrev: ANBL1232
Principal Investigator: Amy A. Smith, MD
Phase: Drug: Phase III
Age Group: Pediatric
Secondary Protocol No: ANBL1232
Treatment: Other: Clinical Observation Other: Laboratory Biomarker Analysis Drug: Chemotherapy (multiple)
Therapies Involved: Chemotherapy
ClinicalTrials.gov ID: NCT02176967
-
Objective
This trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients.
-
Key Eligibility
Ages Eligible for Study: infants Genders eligible for Study: Both Accepts Healthy Volunteers: No
